Search

everythinglearnresearchcommunity

for

Search:↓

"D-CHRAMPS syndrome" is a newly identified condition with multiple severe symptoms.

Dutasteride works better than finasteride for hair loss, with both being safe to use.

AGD1 is important for root hair development in Arabidopsis, working with phosphoinositide signaling and the actin cytoskeleton.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

The treatment was not recommended due to limited effectiveness and significant side effects.

VDDR I and II are genetic disorders affecting vitamin D use, causing rickets, with VDDR I treatable by vitamin D supplements and VDDR II needing high doses and calcium.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Two patients with stubborn hair loss grew hair after PDRN injections.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

A woman lost all her hair in one day, was diagnosed with a rare type of hair loss, and regrew it in 12 weeks with treatment.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Adalimumab may cause severe hair loss in some patients.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.

The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.

Many drugs can cause lipid metabolism issues, and labels need better warnings.

Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.

cp-asiAR may effectively treat hair loss by targeting androgen receptors.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Using anabolic androgenic steroids can cause serious, lasting health problems in many parts of the body.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

5α-reductase enzymes are crucial in certain disorders, and while treatment advances exist, more research on SRD5A3 is needed.

Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.

5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.

Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.